Lesson
Follow Candida Across the Barrier
Candida commonly colonizes skin and the gastrointestinal tract. Invasive disease follows barrier disruption, device biofilm, abdominal leakage, or profound host vulnerability.
- Commensal
- Barrier failure
- Central line
- Biofilm
- Translocation
risk pathogenesis
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Map endogenous entry
Broad-spectrum antibiotics, mucosal injury, abdominal surgery, anastomotic leak, pancreatitis, and parenteral nutrition can permit gastrointestinal Candida to reach sterile sites.
Map device entry
Central venous catheters, dialysis access, prosthetic material, and other devices can introduce skin organisms and support persistent biofilm.
Map host vulnerability
Critical illness, prolonged ICU care, renal replacement, neutropenia, transplantation, malignancy, prematurity, and injection drug use alter both risk and dissemination.
Separate colonization from disease
Candida in sputum usually reflects colonization. Candida from blood or a normally sterile, newly obtained specimen in a compatible syndrome carries different significance.
Quick check
Lesson
Make Every Culture Change the Plan
Blood culture establishes candidemia, but deep candidiasis can remain culture-negative. Species and susceptibility convert a broad initial regimen into definitive therapy.
- Blood culture
- Species
- Susceptibility
- Beta-D-glucan
- Deep tissue
diagnostic evidence
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Obtain and repeat cultures
Collect adequate blood-culture sets before therapy when feasible. After candidemia is identified, repeat cultures daily or every other day until clearance is documented.
Identify the species
C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. auris, and other species have different expected susceptibility and epidemiology.
Request susceptibility
Test azole susceptibility for bloodstream and other clinically relevant isolates. Consider echinocandin testing after prior exposure or with C. glabrata, C. parapsilosis, C. auris, breakthrough, or nonresponse.
Use adjunctive evidence carefully
Beta-D-glucan can support possible invasive fungal disease but is not Candida-specific. Deep abscess, tissue, valve, eye, bone, and CNS disease may require site-directed imaging and specimens.
Quick check
Lesson
Start the Right Echinocandin at the Right Dose
Most adults begin with an echinocandin, then transition only after clinical, microbiologic, source, and compartment evidence supports it.
- Caspofungin
- Micafungin
- Anidulafungin
- Rezafungin
- Fluconazole
initial therapy
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Dose daily echinocandins
Caspofungin uses 70 mg IV once then 50 mg daily. Micafungin uses 100 mg IV daily. Anidulafungin uses 200 mg IV once then 100 mg daily for adult candidemia.
Use rezafungin selectively
Current labeling includes adults and patients age 12 years or older with limited or no alternatives. It is administered once weekly and safety beyond four weekly doses is not established.
Reserve initial fluconazole for selected patients
A stable, noncritically ill adult with low likelihood of fluconazole resistance may receive fluconazole 800 mg once then 400 mg daily, with renal and interaction review.
Do not confuse compartments
Echinocandins have limited urine, vitreous, and CNS exposure. A bloodstream-active regimen may need to change when a deep compartment is identified.
Quick check
Lesson
Control the Source and Start the Clock Correctly
Antifungal activity cannot reliably clear an infected catheter, undrained abscess, leaking anastomosis, or thrombosed vein without source control.
- Repeat cultures
- Central line
- Drainage
- Clearance
- 14 days
clearance source
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Remove an implicated line
In nonneutropenic candidemia, remove the central venous catheter as early as possible when it is the presumed source and removal is safe. Individualize the decision in neutropenia.
Control abdominal sources
Drain abscesses, repair leaks, remove infected material, and distinguish a fresh sterile-site specimen from a long-standing drain culture.
Find the clearance date
Repeat blood cultures daily or every other day. Persistent positivity demands source, drug, species, and deep-site reassessment.
Calculate uncomplicated duration
Treat for 14 days after documented bloodstream clearance and symptom resolution when there is no metastatic complication. Deep sites create different durations.
Quick check
Lesson
Step Down Only When Four Conditions Align
Oral availability is not enough. Stability, susceptibility, bloodstream clearance, and reliable delivery must align before transition.
- Stable
- Susceptible
- Negative cultures
- Fluconazole load
- Follow-up
stepdown exposure
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Confirm clinical stability
The patient should have improving physiology, a controlled source, no unexplained persistent fever, and no deep-site requirement for another agent.
Confirm microbiology
The isolate must be susceptible to the selected oral drug and repeat blood cultures must be negative.
Engineer fluconazole delivery
Use appropriate loading and maintenance, adjust for renal function, and review QT risk, liver tests, CYP interactions, absorption, and adherence.
Plan the remaining course
Document the clearance date, total duration, pending cultures, site follow-up, laboratory schedule, access, and relapse symptoms before discharge.
Quick check
Lesson
Treat Persistence as a Diagnostic Alarm
Ongoing positive cultures are evidence of a remaining source, deep compartment, resistance, or inadequate exposure until proven otherwise.
- Biofilm
- Endocarditis
- Thrombophlebitis
- Abscess
- Resistance
persistent fungemia
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Audit source control
Reassess central and peripheral lines, abdominal leaks or collections, urinary obstruction, devices, prosthetic material, wounds, and injection-related foci.
Search metastatic sites
Use examination and symptoms to guide echocardiography, venous imaging, eye evaluation, abdominal imaging, spine or joint imaging, and neurologic workup.
Audit antifungal exposure
Verify species, MICs, load, daily dose, infusion completion, organ adjustment, interactions, administration, and breakthrough after prior azole or echinocandin exposure.
Escalate expertise
Persistent candidemia warrants infectious-disease, source-control, microbiology, pharmacy, and site-specific specialist involvement.
Quick check
Lesson
Protect the Eye and the Valve
The posterior eye and cardiac valve are compartments where drug penetration, procedures, and duration differ sharply from uncomplicated bloodstream infection.
- Chorioretinitis
- Vitritis
- Endocarditis
- Valve surgery
- Suppression
eye endocardial
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Flag the eye-screening conflict
The 2016 IDSA guideline recommends dilated examination for candidemia. Later ophthalmology guidance argues against routine consultation in asymptomatic patients because yield is low. Use current local guidance, symptoms, host risk, persistence, and specialist input.
Treat ocular disease by anatomy
Chorioretinitis without vitritis can use a susceptible azole or liposomal amphotericin with flucytosine. Vitritis may require intravitreal therapy and vitrectomy in addition to systemic treatment.
Treat endocarditis as a surgical disease
Use early valve or device surgery when feasible plus high-dose echinocandin or lipid amphotericin with flucytosine, followed by susceptible azole step-down after stability and clearance.
Plan prolonged control
Endocarditis requires at least six weeks after valve replacement and longer with complications. If surgery is impossible or prosthetic material remains, chronic suppressive fluconazole may be required when susceptible.
Quick check
Lesson
Match the Drug to the Deep Site
Abdomen, urinary tract, CNS, bone, joint, and hepatosplenic tissue each impose distinct source, exposure, and duration requirements.
- Intra-abdominal
- Urinary
- CNS
- Osteomyelitis
- Hepatosplenic
deep compartments
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Control the abdomen
Drain collections, repair leaks, and remove infected material. Select antifungal therapy using severity, species, susceptibility, prior exposure, and the significance of the specimen.
Respect urinary pharmacology
Echinocandins have poor urinary concentrations. Symptomatic cystitis, pyelonephritis, fungus balls, obstruction, devices, and candidemia require distinct plans using urine-active therapy when indicated.
Protect CNS exposure
CNS disease often begins with liposomal amphotericin plus flucytosine, followed by high-dose susceptible fluconazole after response. Devices and abscesses require procedural assessment.
Treat structural disease long enough
Osteomyelitis, septic arthritis, and hepatosplenic disease require imaging, source procedures, months of therapy, and immune-aware response assessment.
Quick check
Lesson
Adapt the Plan to Immune and Developmental Biology
Neutropenia and neonatal physiology change likely sites, drug exposure, clearance, and the evaluation needed to prove control.
- Neutropenia
- Hepatosplenic
- Neonate
- Lumbar puncture
- Urine culture
neutropenia neonate
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Treat neutropenic candidemia
Use an echinocandin or appropriate alternative, repeat cultures, evaluate sources, and continue through bloodstream and symptom resolution with attention to neutrophil recovery and hepatosplenic disease.
Interpret fever during recovery
Chronic disseminated hepatosplenic candidiasis can become clinically apparent during neutrophil recovery. Imaging and immune trajectory help separate progression from inflammatory unmasking.
Evaluate neonatal dissemination
Neonates need blood and urine cultures, lumbar puncture when feasible, eye assessment, catheter review, and imaging when cultures remain positive.
Use neonatal drug evidence
Amphotericin B deoxycholate or fluconazole are common primary options according to susceptibility and prior prophylaxis. Echinocandin use requires neonatal expertise because CNS and urinary exposure are important.
Quick check
Lesson
Separate Candida auris Infection From Colonization
Candida auris combines invasive-disease risk, multidrug resistance, persistent skin colonization, and healthcare transmission.
- Clinical infection
- Colonization
- Echinocandin
- Resistance
- Infection control
candida auris
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Treat clinical infection
CDC recommends an echinocandin initially for most adults and children older than two months, with careful response and susceptibility monitoring.
Do not treat colonization
A positive screening swab or noninvasive-site result without symptoms is not an indication for antifungal treatment. Colonization can persist despite negative repeat screens.
Respond to resistance
If susceptibility shows echinocandin resistance or the patient does not improve after five days, CDC advises considering liposomal amphotericin B 5 mg/kg daily with expert input.
Protect the healthcare system
Report cases as required, apply recommended precautions and environmental disinfection, flag the record, and communicate infection or colonization status during transfer.
Quick check
Lesson
Prevent the Next Invasive Infection
Many candidemia risks are created or amplified by devices, antibiotics, parenteral nutrition, surgery, and healthcare transmission.
- Line care
- Antibiotic stewardship
- Surgical source
- Prophylaxis
- Surveillance
prevention stewardship
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Protect central lines
Use evidence-based insertion, dressing, hub, access, and daily necessity practices. Remove lines that are no longer needed.
Use antibiotics deliberately
Broad-spectrum antibacterial exposure disrupts flora and selects Candida. Reassess indication, spectrum, route, and duration daily.
Protect abdominal and nutritional care
Prevent leaks, control them early, optimize enteral feeding when appropriate, and minimize unnecessary parenteral-nutrition and device days.
Target prophylaxis
Some transplant, neutropenic, and high-risk ICU populations benefit from prophylaxis, but population incidence, resistance, toxicity, interactions, and local protocols determine value.
Quick check
Lesson
Close the Invasive Candida Loop
A complete plan links cultures, species, source, exact drug, clearance, compartment, transition, duration, resistance, and infection prevention.
- Cultures
- Species
- Source
- Exposure
- Ownership
integrated case
Connect barrier failure, bloodstream clearance, source control, species, and every seeded compartment.
Define the syndrome
Record candidemia versus deep disease, host risk, likely portal, devices, abdominal events, immune status, and every symptom suggesting metastatic spread.
Own microbiology
Track repeat cultures to clearance, species identification, azole and selected echinocandin susceptibility, and any deep-site specimen.
Own treatment delivery
Verify echinocandin loading and maintenance, source control, fluconazole loading and renal adjustment, compartment exposure, interactions, toxicity, access, and adherence.
Own follow-through
Document the clearance date, eye-screening approach and guideline basis, imaging, procedures, deep-site duration, C. auris precautions, transfer communication, and relapse surveillance.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.